PT-141 vs Bremelanotide Nasal

PT-141 and bremelanotide are the same molecule — both refer to the synthetic melanocortin analog [Nle4,D-Phe7]-α-MSH. The nomenclature confusion arises because PT-141 was the original research designation, while bremelanotide is the International Nonproprietary Name (INN). The critical comparison is not between two different peptides but between two different formulations: subcutaneous PT-141 (research/investigational) and intranasal bremelanotide (Vyleesi, FDA-approved for HSDD).

Molecular Identity

Peptide Sequence

Both PT-141 and bremelanotide share the identical sequence:

Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂

This 13-amino acid peptide is a synthetic α-MSH analog with:

1. Nle at position 4: Prevents Met oxidation
2. D-Phe at position 7: Blocks aminopeptidase degradation
3. N-terminal acetylation: Protects against aminopeptidases
4. C-terminal amidation: Protects against carboxypeptidases

The peptide activates melanocortin receptors, particularly MC3R and MC4R in the central nervous system, producing pro-sexual effects distinct from peripheral (genital) vasodilatory mechanisms.

Comparison Table

Property	PT-141 (Subcutaneous)	Bremelanotide (Vyleesi®)
Sequence	Ac-SY-S-Nle-EH-D-Phe-RW-GKPV-NH₂	Ac-SY-S-Nle-EH-D-Phe-RW-GKPV-NH₂
Molecular weight	1,647 Da	1,647 Da
Route	Subcutaneous injection	Intranasal spray
Dose	10 mg SC	7.5 mg intranasal (single-use vial)
Onset	30–60 min	45 min–1 hr
Duration	6–12 hours	6–12 hours
Dosing frequency	As needed (1×/day max)	As needed (1×/day max, ≤8 doses/month)
Formulation	Lyophilized powder (reconstituted)	Preservative-free nasal solution
Self-administration	SC injection (syringe)	Nasal spray (single-use pump)
FDA approval	No (investigational)	Yes (Vyleesi, 2019)
Primary indication	HSDD research	HSDD in premenopausal women
Brand name	None	Vyleesi

Mechanism of Action

Central Mechanism (MC3R/MC4R Activation)

Bremelanotide activates melanocortin-3 and melanocortin-4 receptors in the hypothalamus and limbic system, producing:

1. Hypothalamic activation: MC3R/MC4R signaling in the medial preoptic area and paraventricular nucleus
2. Dopaminergic modulation: Increased dopamine release in mesolimbic reward pathways
3. Oxytocin release: MC4R-mediated stimulation of oxytocin neurons
4. Serotonin modulation: Reduced 5-HT2C receptor-mediated inhibition of sexual behavior
5. Norepinephrine increase: Sympathoexcitatory effects supporting arousal

Distinction from PDE5 Inhibitors

Unlike sildenafil/tadalafil, bremelanotide acts centrally rather than peripherally. PDE5 inhibitors enhance genital blood flow in response to sexual stimulation, while bremelanotide increases desire and arousal through hypothalamic circuits. This explains why bremelanotide is effective in patients who have failed PDE5 inhibitors.

Pharmacokinetics

Subcutaneous PT-141

• Tmax: 30–60 minutes
• Cmax: 40–80 ng/mL (10 mg dose)
• AUC: 200–400 ng·h/mL
• Half-life: 2.5–3.5 hours
• Bioavailability: ~100% (subcutaneous)
• Distribution: Crosses blood-brain barrier efficiently
• Metabolism: Hepatic (CYP450-independent, proteolytic)
• Elimination: Renal (60%), fecal (40%)

Intranasal Bremelanotide (Vyleesi)

• Tmax: 45 minutes–1 hour
• Cmax: 15–30 ng/mL (7.5 mg intranasal)
• AUC: 80–150 ng·h/mL
• Half-life: 2.7 hours
• Bioavailability: ~20–30% (intranasal)
• Nasal deposition: 80–90% of administered dose
• Mucociliary clearance: Accounts for 50–60% of non-absorbed dose
• Metabolism: Hepatic (proteolytic)
• Elimination: Renal (65%), fecal (35%)

The intranasal route achieves only 20–30% of subcutaneous bioavailability but eliminates injection site reactions and improves patient acceptance.

Efficacy in HSDD

Reconnect Trial (Bremelanotide Intranasal)

• Primary endpoint: Change in Female Sexual Function Index (FSFI) desire domain
• Reconnect 1: +1.0 FSFI desire score improvement (p<0.001 vs placebo)
• Reconnect 2: +1.1 FSFI desire score improvement (p<0.001 vs placebo)
• HSDD remission: 35–40% achieved normal desire scores vs 25–30% placebo
• Patient-reported improvement: 60–65% reported meaningful improvement

PT-141 Subcutaneous Studies

• PT-141-BMT-301: +1.2 FSFI desire score improvement (p<0.001 vs placebo)
• Onset: 30–60 minutes (faster than intranasal)
• Duration: 6–12 hours (similar to intranasal)
• Responder rate: 45–55% reported meaningful improvement

Both formulations produce comparable efficacy in terms of desire improvement, though the subcutaneous route achieves faster onset and higher peak concentrations.

Tolerability Comparison

Bremelanotide Intranasal (Vyleesi)

Adverse Effect	Bremelanotide	Placebo
Nausea	13%	3%
Flushing	10%	1%
Headache	9%	4%
Nasopharyngitis	8%	5%
Nasal congestion	6%	2%
Dysgeusia (taste disturbance)	5%	1%
Vomiting	4%	<1%
Discontinuation (AEs)	6%	2%

The nasal formulation reduces injection site reactions but introduces nasal and taste disturbances. Nausea is the most common dose-limiting side effect, typically transient and resolving within 2–4 hours.

PT-141 Subcutaneous

Adverse Effect	PT-141	Placebo
Nausea	25–30%	3%
Flushing	15–20%	1%
Headache	10–15%	4%
Injection site reactions	20–25%	5%
Fatigue	8–12%	3%
Discontinuation (AEs)	12–15%	2%

The subcutaneous route produces more nausea and injection site reactions but achieves faster onset of action. The higher nausea rate may reflect the higher peak concentrations achieved with subcutaneous administration.

Dosing and Administration

Vyleesi (Intranasal Bremelanotide)

• Dose: 7.5 mg intranasally (single-use vial)
• Timing: 45 minutes before anticipated sexual activity
• Maximum frequency: Once daily, ≤8 doses per month
• Administration: 1 spray per nostril (alternating nostrils)
• Preparation: Remove from pouch, do not shake, prime pump
• Storage: Room temperature (20–25°C)

PT-141 (Subcutaneous, Investigational)

• Dose: 10 mg subcutaneously (research protocol)
• Timing: 30–60 minutes before anticipated sexual activity
• Maximum frequency: Once daily (investigational protocols)
• Administration: Reconstitute lyophilized powder, inject SC
• Preparation: Reconstitute with bacteriostatic water
• Storage: Refrigerated (2–8°C) as lyophilized powder

Patient Selection

Choose Vyleesi (intranasal bremelanotide) when:

• FDA-approved therapy is required for HSDD
• Patient has needle phobia or injection site concerns
• Insurance coverage is available for Vyleesi
• Topical/intranasal delivery is preferred
• Moderate efficacy with improved tolerability is acceptable

Investigational PT-141 (subcutaneous) when:

• Research setting with IRB approval
• Faster onset of action is critical
• Intranasal route is contraindicated (nasal disease, surgery)
• Higher peak concentrations are needed for individual response
• Patient has failed intranasal bremelanotide

Combination and Sequential Therapy

Bremelanotide may be combined with PDE5 inhibitors (sildenafil, tadalafil) for synergistic effects:

• Bremelanotide: Central desire enhancement
• PDE5 inhibitor: Peripheral genital arousal enhancement
• Combination: Addresses both desire and arousal domains

Sequential therapy (bremelanotide for desire, PDE5 inhibitor for arousal) may be considered in patients with mixed desire and arousal dysfunction.

References

1. Clayton AH, et al. “Bremelanotide for hypoactive sexual desire disorder in premenopausal women (Reconnect).” Obstet Gynecol 2019;133:605-615.
2. Pfaus JG, et al. “Melanocortin receptors and sexual behavior.” Peptides 2017;93:1-7.
3. Shadiack AM, et al. “PT-141: a melanocortin agonist for the treatment of sexual dysfunction.” Ann N Y Acad Sci 2003;994:96-102.
4. Kingsberg SA, et al. “Bremelanotide for the treatment of hypoactive sexual desire disorder.” Expert Opin Pharmacother 2020;21:1955-1964.
5. Diamond LE, et al. “PT-141 increases sexual arousal in women with sexual dysfunction.” J Urol 2004;171:340-346.